Welcome to the ZILRETTA Virtual Booth

This page serves as a central location for select resources that will help you and your team to learn more about ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), the first and only approved treatment for osteoarthritis (OA) knee pain utilizing extended-release microsphere technology.*

Request a rep and sign up to receive the latest information about ZILRETTA and to learn more about how to use ZILRETTA for OA knee pain treatment.

*ZILRETTA is not interchangeable with other formulations of injectable triamcinolone acetonide.

INDICATION AND SELECT IMPORTANT SAFETY INFORMATION

Indication ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

Contraindication ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids, or any components of the product.

Please see full Important Safety Information below and link to full Prescribing Information.

Click any of the resources below to download and learn more

ZILRETTA Quick Facts

key facts image

Review key facts about ZILRETTA, including efficacy, safety, and key data.

DOWNLOAD

SEE HOW ZILRETTA WORKS

Discover how ZILRETTA leverages its novel extended-release microsphere technology. *ZILRETTA is not interchangeable with other formulations of injectable triamcinolone acetonide.

SEE MORE

HEAR ABOUT ROD WOODSON’S ZILRETTA EXPERIENCE

Meet retired NFL player and Hall of Fame Member Rod Woodson and hear him share his experience with using ZILRETTA for his osteoarthritis knee pain.

SEE MORE

Simplify Coding & Billing

simplify coding and billing image

Coding and billing can be confusing and time-consuming; this resource can help your team simplify the coding process and ensure that your patients are receiving the best treatment experience.

DOWNLOAD

Our Distribution Network

Our Distribution Network image

Our network of experienced specialty distributors makes ordering ZILRETTA a seamless part of treating your patients’ OA knee pain.

DOWNLOAD

Bulk Pricing Information

Bulk Pricing Information image

This resource provides practices interested in ZILRETTA with an outline of rebate offers for bulk purchasing.

DOWNLOAD

Meet the Z TeamSM

Meet the Z Team image

Help your patients feel supported along every step of their journey with the Z Team, a dedicated patient concierge program that connects patients to healthcare providers who have experience with ZILRETTA.

DOWNLOAD

FlexForward® Support Program

flex forward support program image

Learn about the FlexForward® program designed to help support you with your commercial and Medicare Advantage patients.

DOWNLOAD

SAME DAY INJECTION PROGRAM

SAME DAY INJECTION PROGRAM image

If your patients have a commercial health plan, they could qualify for a ZILRETTA injection the same day as their initial appointment. Learn more about the Same Day Injection Program here.

DOWNLOAD

Indication and Important Safety Information

Indication ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

Contraindication ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids, or any components of the product.

Warnings and Precautions

  • Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. Serious events have been reported with epidural and intrathecal administration of corticosteroids and none are approved for this use. ZILRETTA should not be considered safe for epidural or intrathecal administration.
  • Hypersensitivity Reactions: Rare instances of anaphylaxis, including serious cases, have occurred in patients with hypersensitivity to corticosteroids.
  • Joint Infection and Damage: A marked increase in pain accompanied by local swelling, restriction of joint motion, fever, and malaise are suggestive of septic arthritis. Examine joint fluid to exclude a septic process. If diagnosis is confirmed, institute appropriate antimicrobial therapy. Avoid injecting corticosteroids into a previously infected or unstable joint. Intra-articular administration may result in damage to joint tissues.
  • Increased Risk of Infections: Infection with any pathogen in any location of the body may be associated with corticosteroid use. Corticosteroids may increase the susceptibility to new infection and decrease resistance and the ability to localize infection.
  • Alterations in Endocrine Function: Corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression, with potential for adrenal insufficiency after withdrawal of treatment, which may persist for months. In situations of stress during that period, institute corticosteroid replacement therapy.
  • Cardiovascular and Renal Effects: Corticosteroids can cause blood pressure elevation, salt and water retention, and increased potassium excretion. Monitor patients with congestive heart failure, hypertension, and renal insufficiency for edema, weight gain, and electrolyte imbalance. Dietary salt restriction and potassium supplementation may be needed.
  • Increased Intraocular Pressure: Corticosteroid use may be associated with increased intraocular pressure. Monitor patients with elevated intraocular pressure for potential treatment adjustment.
  • Gastrointestinal Perforation: Corticosteroid administration may increase risk of gastrointestinal perforation in patients with certain GI disorders and fresh intestinal anastomoses. Avoid corticosteroids in these patients.
  • Alterations in Bone Density: Corticosteroids decrease bone formation and increase bone resorption. Special consideration should be given to patients with or at increased risk of osteoporosis prior to treatment.
  • Behavior and Mood Disturbances: Corticosteroids may cause adverse psychiatric reactions. Prior to treatment, special consideration should be given to patients with previous or current emotional instability or psychiatric illness. Advise patients to immediately report any behavior or mood disturbances.

Adverse Reactions The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis, cough, and contusions.

Link to full Prescribing Information.

request a rep icon

© 2021 Flexion Therapeutics, Inc. All rights reserved. Z Team is a service mark of Flexion Therapeutics, Inc. ZILRETTA and FLEXFORWARD are registered marks of Flexion Therapeutics, Inc. March 2021. Z-01359